Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
BMC Pregnancy Childbirth ; 23(1): 723, 2023 Oct 11.
Article in English | MEDLINE | ID: mdl-37821915

ABSTRACT

BACKGROUND: Whether intrauterine transmission of COVID-19 occurs remains uncertain, and it remains unclear whether the disease affects fetuses. We present a case of intrauterine transmission of SARS-CoV-2 infection and the prenatal ultrasonographic findings of the fetus in a pregnant woman with mild COVID-19. CASE PRESENTATION: A 30-year-old woman was admitted to our hospital for ultrasound examination in January 2023 at 26+ 3 weeks' gestation. Twenty-one days prior, her COVID-19 nucleic acid test was positive, and she had mild symptoms, including fever (38.3 °C), headache, chills, ankle pain and cough. After receiving symptomatic treatment, she fully recovered. Prenatal ultrasound revealed that the placenta was diffusely distributed with punctate echogenic foci, hepatomegaly, and the volume of bilateral lungs decreased significantly, with enhanced echo. In addition, we found that the surface of the fetal brain demonstrated widened gyri with a flattened surface. The prenatal MRI confirmed these fetal abnormalities. Amniotic fluid was tested for SARS-CoV-2, and the sample tested was positive for the virus. After careful consideration, the pregnant woman decided to terminate the pregnancy. CONCLUSION: The intrauterine transmission of COVID-19 is certain. Moreover, the intrauterine transmission of COVID-19 may cause abnormalities in various organs of the fetus.


Subject(s)
COVID-19 , Pregnancy Complications, Infectious , Female , Pregnancy , Humans , Adult , SARS-CoV-2 , Pregnant Women , Pregnancy Complications, Infectious/diagnosis , Fetus , Placenta/diagnostic imaging , Amniotic Fluid , Infectious Disease Transmission, Vertical , Ultrasonography, Prenatal
2.
J Ethnopharmacol ; 202: 103-113, 2017 Apr 18.
Article in English | MEDLINE | ID: mdl-28238827

ABSTRACT

ETHNOPHARMACOLOGICAL RELEVANCE: Rhizoma Smilacis Glabrae (RSG) is traditionally used to treat gynecological disease, which is simply recorded in Chinese Pharmacopoeia. However, whether it has effect on upper genital tract inflammation (UGTI) is unclear. AIM OF THE STUDY: To evaluate the pharmacological effect of RSG on UGTI in rats and analyze its phytochemistry characteristics. MATERIALS AND METHODS: The substances in RSG extract was qualified by LC-Q-TOF-MS method, and 11 substances were further quantified. The RSG extract, at dose of 241, 482 (clinical dose) and 964mg/kg/day, was orally administered to UGTI rats whose upper genital tracts were multi-infected with pathogens. Infiltrations of neutrophil and lymphocyte and productions of IL-1ß, IL-6, CXCL-1, MCP-1, RANTES, PGE2, COX-2, NF-κB p65 and IκB-α in upper genital tract were examined to evaluate the effects of RSG and its potential mechanism. RESULTS: A total of 77 substances were detected in RSG extract, with 50 substances putatively identified, most of which were flavonoids, phenolic acids and phenylpropanoids. The quantification analysis showed flavonoid had a relative high amount. In pharmacological study, RSG extract suppressed infiltrations of inflammatory cells, reduced over-productions of factors involved in inflammation and pelvic pain. A potential mechanism of these effects was blocking NF-κB signal pathway. CONCLUSIONS: The RSG extract exhibited anti-inflammatory effect on UGTI, with a potential mechanism of blocking the activation of NF-κB signal pathway. The effect may be involved in the presence of substances, such as flavonoids and phenolic acids.


Subject(s)
Drugs, Chinese Herbal/therapeutic use , Genital Diseases, Female/drug therapy , NF-kappa B/drug effects , Animals , Chemokines/biosynthesis , Cyclooxygenase 2/biosynthesis , Cytokines/biosynthesis , Dinoprostone/biosynthesis , Drugs, Chinese Herbal/chemistry , Female , Genital Diseases, Female/metabolism , Genital Diseases, Female/microbiology , Inflammation/drug therapy , Inflammation/microbiology , Inflammation/pathology , Pelvic Pain/drug therapy , Plant Extracts/pharmacology , Plant Extracts/therapeutic use , Rats , Rats, Sprague-Dawley , Signal Transduction/drug effects
3.
Drug Des Devel Ther ; 9: 2375-82, 2015.
Article in English | MEDLINE | ID: mdl-25987835

ABSTRACT

Apolipoprotein M (ApoM) is predominantly located in the high-density lipoprotein in human plasma. It has been demonstrated that ApoM expression could be regulated by several crucial nuclear receptors that are involved in the bile acid metabolism. In the present study, by combining gene-silencing experiments, overexpression studies, and chromatin immunoprecipitation assays, we showed that ApoM positively regulated liver receptor homolog-1 (LRH-1) gene expression via direct binding to an LRH-1 promoter region (nucleotides -406/ -197). In addition, we investigated the effects of farnesoid X receptor agonist GW4064 on hepatic ApoM expression in vitro. In HepG2 cell cultures, both mRNA and protein levels of ApoM and LRH-1 were decreased in a time-dependent manner in the presence of 1 µM GW4064, and the inhibition effect was gradually attenuated after 24 hours. In conclusion, our findings present supportive evidence that ApoM is a regulator of human LRH-1 transcription, and further reveal the importance of ApoM as a critical regulator of bile acids metabolism.


Subject(s)
Apolipoproteins/physiology , Lipocalins/physiology , Receptors, Cytoplasmic and Nuclear/physiology , Apolipoproteins/genetics , Apolipoproteins/metabolism , Apolipoproteins M , Bile Acids and Salts/metabolism , Chromatin Immunoprecipitation , Gene Expression Regulation/drug effects , Gene Silencing , Hep G2 Cells , Humans , Isoxazoles/pharmacology , Lipocalins/genetics , Lipocalins/metabolism , Liver/metabolism , Plasmids/genetics , Promoter Regions, Genetic/physiology , RNA, Messenger/biosynthesis , Receptors, Cytoplasmic and Nuclear/agonists , Receptors, Cytoplasmic and Nuclear/metabolism , Transfection
SELECTION OF CITATIONS
SEARCH DETAIL
...